Clinical trials: Gametocytes
Malaria,Falciparum, Gametocytes
Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2
This is a single-center, open label study. The primary aim of this project is to develop a controlled human malaria infection transmission model ("CHMI-trans") or "challenge model" to evaluate the capacity of vaccines, biologics…
- Conditions
- Malaria,Falciparum, Gametocytes, Controlled Human Malaria Infection, Transmission
- Trial name
- CHMI-trans2 (NCT03454048)
- Testing
- Piperaquine (low dose), Piperaquine (high dose), Sulfadoxine pyrimethamine
- Where
- Netherlands
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Malaria
P. Falciparum Infection Dynamics and Transmission to Inform Elimination
In the current study, three experimental approaches aiming at reducing malaria transmission will be tested. The study will cover two transmission season (2019 and 2020) and the interventions will vary by season.
- Trial name
- INDIE-1b (NCT04053907)
- Testing
- Community Case Management, Weekly fever screening and treatment, Monthly malaria screening
- Where
- The Gambia
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria,Falciparum
Controlled Human Malaria Infection Transmission Model - Phase A
This is to develop a model to test the efficacy of vaccines and/or drugs designed to block transmission of malaria to mosquitoes and to identify the targets of transmission-blocking immunity to malaria.
- Trial name
- CHMI-TransMod (NCT04280692)
- Testing
- PfSPZ Challenge, Sulfadoxine-Pyrimethamine, Piperaquine
- Where
- Kenya
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria
Phase 2 Efficacy Study of Primaquine and Methylene Blue
The purpose of this study is to determine the most efficacious transmission blocking drug regimen for seasonal malaria chemoprophylaxis in Mali.
- Trial name
- NCT02831023
- Testing
- Sulphadoxine-pyrimethamine, 0.25 mg/kg primaquine, Dihydroartemisinin-piperaquine
- Where
- Mali
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Asymptomatic P.Falciparum Malaria
Effect of Antimalarial Treatment on Gametocyte Carriage in Asymptomatic P. Falciparum
Treatment of uncomplicated P.falciparum malaria with sulfadoxine-pyrimethamine (SP) is followed by a marked increase in the density of gametocytes.
- Trial name
- NCT00289250
- Testing
- Sulfadoxine-pyrimethamine, Sulfadoxine-pyrimethamine plus artesunate
- Where
- The Gambia
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria,Falciparum
Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics of TB31F
This phase 1 study aims to assess the safety and tolerability of monoclonal antibody TB31F administered intravenously or subcutaneously at escalating dose levels in healthy, malaria naïve, adults.
- Trial name
- TB31F (NCT04238689)
- Testing
- TB31F
- Where
- Netherlands
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Malaria
Primaquine's Gametocytocidal Efficacy in Malaria Asymptomatic Carriers
In this study, the investigators are interested to know if lower doses of Primaquine together with dihydroartemisinin-piperaquine can produce a similar effect of clearing both sexual and asexual parasites in asymptomatic carriers…
- Trial name
- PRINOGAM (NCT01838902)
- Testing
- DHA-PPQ, PQ (0.75), PQ (0.4)
- Where
- The Gambia
- Volunteers
- 467 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria
Preventing the Spread of Malaria in Mali
A vaccine which interrupts malaria transmission is a critical tool to achieve the ultimate goal of eradication of this disease. Transmission blocking vaccines work by inducing antibody in vaccinated individuals that inhibits the…
- Trial name
- NCT01360112
- Where
- Mali
- Volunteers
- 816 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
P. Falciparum Infection Dynamics and Transmission to Inform Elimination (INDIE-1a)
In the current randomized trial, the investigators will test the ability of two experimental approaches to malaria infection management to reduce malaria transmission potential.
- Trial name
- NCT03705624
- Testing
- Enhanced Community Case Management (CCM), Monthly Screening and Treatment (MSAT)
- Where
- Burkina Faso
- Volunteers
- 907 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria, Asymptomatic Malaria
Low Dose Primaquine for Clearance of Gametocytes
Primaquine (PQ) is currently the only available drug that can clear mature transmission stages of P. falciparum parasites. PQ was previously shown to clear gametocytes that persist after artemisinin-combination therapy.
- Conditions
- Malaria, Asymptomatic Malaria, Plasmodium Falciparum
- Trial name
- LOPRIM (NCT01935882)
- Testing
- Artemether-lumefantrine combination, Artemether-Lumefantrine with a single dose of 0.25mg/kg primaquine, Artemether-Lumefantrine with a single dose of 0.4mg/kg primaquine
- Where
- Burkina Faso
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria
Community Dynamics of Malaria Transmission in Humans and Mosquitoes at Maferinyah Sub-Prefecture, Guinea
Background: Half of the world s population is at risk of malaria. In 2015, there were 214 million cases of malaria and 438,000 deaths. A transmission-blocking vaccine (TBV) could help end the disease.
- Trial name
- NCT04969913
- Where
- 2 sites in United States, Guinea
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria,Falciparum
Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission
The purpose of this study is to assess the gametocytocidal and transmission reducing activity of pyronaridine-artesunate (PA) and dihydroartemisinin-piperaquine (DP) with and without a single low dose of primaquine (PQ…
- Trial name
- NECTAR1 (NCT04049916)
- Testing
- Pyronaridine Tetraphosphate/Artesunate, Dihydroartemisinin/Piperaquine, Primaquine Diphosphate
- Where
- 2 sites in Mali, Netherlands
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine